Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
PLoS One. 2023 Jun 22;18(6):e0287575. doi: 10.1371/journal.pone.0287575. eCollection 2023.
Pharmacotherapy is necessary for many people with psychiatric disorders and polypharmacy is common. The psychotropic drug-drug interaction (DDI) should be concerned and efficiently monitored by a proper instrument.
This study aimed to investigate the prevalence and associated factors of psychotropic DDI and to compare the identification utility from three databases: Drugs.com®, Lexicomp®, and Epocrates®.
This was a retrospective cohort design. We collected demographic and clinical data of all patients hospitalised in the psychiatric inpatient unit in 2020. Psychotropic DDI profiles were examined through three databases. Descriptive statistics were used to report comprehensiveness of each database and prevalence of psychotropic DDI. The Fleiss' kappa index would be analysed to indicate agreement strength of DDI severity classification among three databases.
From 149 total admissions, the psychotropic DDIs were found in 148 admissions (99.3%). Thorough the study, there were 182 of both psychotropic and other agents prescribed under 1,357 prescriptions. In total, 2,825 psychotropic DDIs were identified by using Drugs.com® 2,500 times, Epocrates® 2,269 times, and Lexicomp® 2,265 times. Interactions with clonazepam was the three most frequent agents when co-administrated with quetiapine (n = 56), risperidone (n = 36), and valproic acid and derivatives (n = 36). Serious DDIs were comparatively lower in incidence and there was no evidence of its association with reported clinical adverse consequences. The study revealed slight and fair agreement regarding severity classification among the three databases was found. DDI events detected by Drugs.com® were greatest in number, but Lexicomp® provided the broadest list of medications prescribed in our study.
Among three databases, interactions detected by Drugs.com® were greatest in number, whereas Lexicomp® provided the broadest list of medications. Development of such databases, based on both theoretical and clinical conceptions, should be focused to balance safety of patients and weariness of healthcare providers.
精神障碍患者通常需要药物治疗,且常合并用药。应使用适当的工具来关注和有效地监测精神药物药物相互作用(DDI)。
本研究旨在调查精神药物 DDI 的流行率及其相关因素,并比较三个数据库(Drugs.com®、Lexicomp®和 Epocrates®)的识别效果。
这是一项回顾性队列设计。我们收集了 2020 年在精神科住院病房住院的所有患者的人口统计学和临床数据。通过三个数据库检查精神药物 DDI 谱。使用描述性统计来报告每个数据库的全面性和精神药物 DDI 的流行率。Fleiss' kappa 指数用于分析三个数据库中 DDI 严重程度分类的一致性强度。
在 149 例总入院病例中,148 例(99.3%)存在精神药物 DDI。在研究过程中,有 182 种精神药物和其他药物在 1357 张处方中被开具。使用 Drugs.com® 2500 次、Epocrates® 2269 次和 Lexicomp® 2265 次,共发现 2825 种精神药物 DDI。当氯硝西泮与喹硫平(n=56)、利培酮(n=36)和丙戊酸及其衍生物(n=36)联合使用时,与氯硝西泮的相互作用是三种最常见的联合药物。严重 DDI 的发生率较低,且没有证据表明其与报告的临床不良后果有关。研究发现,三个数据库之间的严重程度分类存在轻微到适度的一致性。Drugs.com® 检测到的 DDI 数量最多,但 Lexicomp® 提供了我们研究中开出处方最多的药物清单。
在三个数据库中,Drugs.com® 检测到的相互作用数量最多,而 Lexicomp® 提供了最广泛的处方药物清单。应该基于理论和临床概念开发此类数据库,以平衡患者的安全性和医疗保健提供者的疲劳感。